Kala’s dry eye treatment nears potential US launch before 2021

Susan Coultas, PhD (top left), and Preeya Gupta, MD (bottom, middle) , discuss Kala Pharmaceuticals’ dry eye product candidate in a poster presentation—“Safety and Efficacy of KPI-121 0.25% for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease in Three Large Multicenter Randomized Controlled Trials”—during the 2020 Women in Ophthalmology virtual summer symposium with Sheryl Stevenson, group editorial director, Ophthalmology Times®.